微信直播

AME译者招募:非小细胞肺癌的小分子靶向治疗药物临床研究

Published at: 2015年第1卷第S1期

关键词:

近年来,全球肺癌发病率居高不下。据《中国 2011 年恶性肿瘤登记年报》报告,2011 年我国肺癌发病率为 48.32/10 万,死亡率为 39.27/10 万。发病率和死亡率均居恶性肿瘤的首位。

在众多肺癌中,非小细胞肺癌(non-small cell lung cancer, NSCLC)占肺癌患者的 85% 左右,大多数就诊时已属晚期,失去了手术治疗的机会。化疗是晚期 NSCLC 治疗的主要手段,其地位虽然没有发生根本改变,但其疗效已达到平台,同时化疗的毒副反应也限制了其广泛的临床应用。

与此同时,随着精准医学的快速发展,根据患者的基因信息来制定、调整治疗方案的小分子靶向治疗药物成为 NSCLC 治疗的新常态,突破了传统化疗药物的瓶颈,是晚期 NSCLC 治疗不可或缺的重要手段。

一时间,就NSCLC的如EGFR基因突变、ALK基因重排、ROS1基因重排、RAS突变和C-MET基因扩增等各个靶点展开的小分子靶向治疗药物相关临床试验紧锣密鼓在全球范围内展开,如在第十七届世界肺癌大会(WCLC2016)上大放异彩的AURA3研究、ASCEND-4研究;PROFILE 1014 研究、JMIT 研究等。

不仅如此,各平台就NSCLC小分子靶向治疗药物临床研究也展开了激烈的讨论,在讨论中迸发新的思想火花。也正是这样一个个跨国、多中心临床研究的开展,围绕临床研究展开的百家争鸣讨论,一步步推动着NSCLC治疗取得不断进步。

为此,AME出版社将就最新NSCLC的小分子靶向治疗药物的重磅临床研究展开专题讨论。

现诚邀国内外该领域优秀医学工作者参与该专题的翻译工作!

此专题待翻译文章目录如下,欢迎各位认领:

编号

文章题目

1

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer

2

AURA3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

3

Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI

4

Osimertinib for EGFR T790M positive non-small cell lung cancer-maing it happen, turning good idea into great results

5

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study

6

Ceritinib: a new first-line therapy against ALK-rearranged lung cancer?

7

What is the optional first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

8

What can we learn from 3 phase III trial of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexe, and J-ALEX: alertinib vs. crizotinib?

9

Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients

10

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014

11

Systematic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases

12

Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials

13

Crizotinib for ALK rearrangement-positibe non-small cell lung cancer patients with central nervous system metastasis

14

Intracranial activity of crizotinib: something to rely on?

15

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activatin Epidermal Growth Factor Receptor Mutations

16

Gefitinib with pemetrexed as first-line therapy in patiens with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

17

A potential new therapeutic option for patients with advance EGFR mutation-positive non-small cell lung cancer in first-line setting

18

Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?

19

Gefitinib in combination with pemetrexed in patients with advanced non-small cell lung cancer harboring EGFR mutations: is there any difference in acquired resistance mechanism between gefitinib monotherapy and the combination treatment?

认领方法:

  1. 下载译者报名表(http://rlxt.amegroups.cn/#notices/9),填写完毕后发送到:rlxt@amegroups.com

  2. 编辑部会综合选择最匹配的专家参与翻译,并给符合要求的专家注册系统账号和获取稿件等信息;

  3. 每位会员/译者认领的书籍和文章均不得超过3本/3篇,编辑部将会对超出译者做出适当的调整;

  4. 注:凡是通过编辑部审核并注册系统账号的专家,我们将会在系统委员风采上展示您的个人风采(包括姓名,科室和简介)

  • 认领截止日期:本次认领长期有效,直至认领完毕。

  • 认领成功后,请在认领成功后的三周内将翻译稿及个人简介上传到系统;并发送到rlxt@amegroups.com

凡翻译质量通过审核的译者,可获得:

  1. 每翻译一篇文章,即可获得价值200元人民币的科研时间积分(200快币),可换购各种图书/杂志,免费登录视频数据库ASVIDE,观看手术视频(积分限免)。

  2. 译者署名权。

comments powered by Disqus

附件